Published in TB and Outbreaks Week, October 16th, 2001
This second Phase III IRDS trial is designed to demonstrate the safety and non-inferiority of Surfaxin, Discovery's humanized, synthesized, peptide-containing surfactant, over a leading animal-derived surfactant in Europe thus providing support to Discovery's previously announced pivotal Phase III multinational IRDS clinical trial. Approximately 500 patients in Europe as well as the United States will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week